Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03992183 · ClinicalTrials.gov registry record
Utility of CAML as Diagnostic for Early Stage Lung Cancer
A clinical trial, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- 200
- Enrollment target
NCT03992183 is a clinical trial that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 200 participants.
The verdict
NCT03992183 was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- 200 participants
- Enrollment target
Study Summary
Primary Objective Determine the prevalence of CAMLS in patients with pulmonary nodules. Secondary Objectives Determine the positive and negative predictive value of CAMLS in patients with pulmonary nodules who undergo biopsy. Model combinations of clinical factors with the presence/absence of CAMLS to refine strategies for assessment of patients with pulmonary nodules. Evaluate whether these measures result in enhanced T-cell activity and/or NK cell function and number
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2019-05-21 |
| Est. Completion | 2022-11-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03992183
The ClinicalTrials.gov registry entry for NCT03992183 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03992183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03992183 about?
NCT03992183 is a clinical study titled "Utility of CAML as Diagnostic for Early Stage Lung Cancer". Primary Objective Determine the prevalence of CAMLS in patients with pulmonary nodules. Secondary Objectives Determine the positive and negative predictive value of CAMLS in patients with pulmonary nodules who undergo biopsy. Model combinations of clinical factors with the presence/absence of CAML...
What is the current status of trial NCT03992183?
This trial is currently terminated. The enrollment target is 200 participants. The study started on 2019-05-21. Estimated completion is 2022-11-14.
Who is sponsoring clinical trial NCT03992183?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.